Arrowhead Pharmaceuticals(NASDAQ) ARWR

Arrowhead Pharmaceuticals makes medicines that treat serious diseases by silencing specific genes. These therapies help patients by stopping the production of proteins that cause illness. The company uses a natural process called RNA interference to target these genes directly.

The Product Pipeline

• REDEMPLO: FDA-approved treatment for adults with Familial Chylomicronemia Syndrome, a rare condition that causes high triglyceride levels.
• Cardiometabolic Candidates: Experimental drugs like plozasiran and zodasiran designed to treat severe heart and blood fat disorders.
• Liver Disease Therapies: Treatments such as fazirsiran, developed to address liver damage caused by genetic protein deficiencies.
• Pulmonary and Muscle Research: Early-stage programs targeting lung diseases like asthma and muscle-wasting conditions like myotonic dystrophy.

Recent Partnerships and Milestones

• Closed a global licensing agreement with Novartis in October 2025 for preclinical programs focused on the central nervous system.
• Earned a $200 million milestone payment from Sarepta Therapeutics in November 2025 for progress in muscle disease clinical trials.
• Received FDA approval for REDEMPLO on November 18, 2025, following successful Phase 3 clinical results.
• Out-licensed rights for plozasiran in Greater China to Sanofi through a subsidiary asset sale in August 2025.

What Makes Arrowhead Unique

The company uses its proprietary TRiM platform to develop therapies that target multiple organs beyond the liver, including the lungs and muscles. It operates its own manufacturing and laboratory facilities in Wisconsin to support the production of its genetic medicine pipeline.

By the Numbers

• Revenue rose to $264 million in Q1 2026, up from $2.5 million in Q1 2025.
• Net income reached $31 million in Q1 2026, compared to a net loss of $173 million in Q1 2025.
• Free cash flow turned positive at $11 million in Q1 2026, up 107% from the previous year.
• Cash and investments totaled $917 million as of December 31, 2025, to fund ongoing clinical research.
• Market capitalization grew to $9.3 billion in Q1 2026, a 296% increase year-over-year.

Bottom Line

Arrowhead has transitioned from a research-focused firm to a commercial-stage company with its first FDA-approved product. Its strategy relies on high-value collaborations with major drugmakers to fund a broad range of genetic therapies.